Provided by Tiger Trade Technology Pte. Ltd.

Foghorn Therapeutics Inc.

4.85
-0.2200-4.34%
Post-market: 4.850.00000.00%19:34 EDT
Volume:122.07K
Turnover:594.75K
Market Cap:284.12M
PE:-4.15
High:5.08
Open:5.03
Low:4.76
Close:5.07
52wk High:6.95
52wk Low:3.27
Shares:58.58M
Float Shares:28.87M
Volume Ratio:0.48
T/O Rate:0.42%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1692
EPS(LYR):-1.1800
ROE:-470.38%
ROA:-21.00%
PB:-3.72
PE(LYR):-4.11

Loading ...

Analysts’ Top Healthcare Picks: Lemaitre Vascular (LMAT), Foghorn Therapeutics (FHTX)

TIPRANKS
·
Jul 20

Foghorn Therapeutics Shareholders Elect Directors at Annual Meeting

Reuters
·
Jun 25

Foghorn Therapeutics to present at Goldman Sachs Global Healthcare Conference 2026

Reuters
·
Jun 05

Foghorn Therapeutics joins Stifel Virtual Targeted Oncology Forum lineup

Reuters
·
May 12

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May

GlobeNewswire
·
May 12

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 08

Analysts Offer Insights on Healthcare Companies: Foghorn Therapeutics (FHTX) and Monte Rosa Therapeutics (GLUE)

TIPRANKS
·
May 08

Foghorn Therapeutics Highlights Q1 Progress in Oncology Pipeline

TIPRANKS
·
May 07

Foghorn Therapeutics Q1 FY26 net loss widens to $19.9 million; revenue falls 45% to $3.3 million

Reuters
·
May 07

Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update

THOMSON REUTERS
·
May 07

Foghorn Therapeutics announces annual shareholder meeting via webcast

Reuters
·
Apr 30

Foghorn Highlights Preclinical Chromatin Oncology Advances at AACR

TIPRANKS
·
Apr 22

Foghorn reports preclinical data for SMARCA2 inhibitor FHD-909 in mouse models

Reuters
·
Apr 22

Foghorn presents new preclinical data for SMARCA2 inhibitor FHD-909 at AACR 2026

Reuters
·
Apr 09

Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting

GlobeNewswire
·
Apr 09

4D Molecular Therapeutics names CFO Kristian Humer principal accounting officer

Reuters
·
Mar 31

Foghorn Therapeutics Price Target Maintained With a $10.00/Share by Wedbush

Dow Jones
·
Mar 12

Foghorn Therapeutics (FHTX) Receives a Buy from Guggenheim

TIPRANKS
·
Mar 12

Buy Rating on Foghorn Therapeutics Driven by Lilly Partnership Catalyst, Advancing Degrader Pipeline, and Strengthened Cash Runway

TIPRANKS
·
Mar 12

Foghorn Advances FHD-909 Trial and Strengthens Financial Position

TIPRANKS
·
Mar 12